Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 3 5Phase 1/2 3

Status

Recruiting 2Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 4Sarcoma 1

Conditions

Small Cell Lung Carcinoma 3Neoplasms 1Lung Neoplasms 1Leiomyosarcoma 1Extensive Stage Small Cell Lung Cancer (ES-SCLC) 1Carcinoma, Small Cell 1

Interventions

Carboplatin 129pembrolizumab 124Cisplatin 114Paclitaxel 102Gemcitabine 85Specimen Handling 80Magnetic Resonance Spectroscopy 80Docetaxel 70Dexamethasone 59Cyclophosphamide 59Pemetrexed 55Bevacizumab 54durvalumab 53Doxorubicin 52Radiotherapy 49Capecitabine 49Radiation 47Oxaliplatin 47Fluorouracil 47Rituximab 42Leucovorin 42Vincristine 41Lenalidomide 40Etoposide 38Letrozole 36atezolizumab 35Nivolumab 35Prednisone 31Bortezomib 31130-nm albumin-bound paclitaxel 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × PM 01183 × 90 days × Clear all
NCT07625644 2026-06-04

Evaluate BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer

SystImmune Inc.

Phase 3 Not yet recruiting
550 enrolled
Thoracic

Lung Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma

NCT06203210 2026-06-02

IDeate-Lung02

Daiichi Sankyo

Phase 3 Recruiting
540 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT06801834 2026-05-20

EVOKE-SCLC-04

Gilead Sciences

Phase 3 Recruiting
695 enrolled
Thoracic

Extensive Stage Small Cell Lung Cancer (ES-SCLC)

NCT06088290 2026-05-15

SaLuDo

PharmaMar

Phase 3 Active not recruiting
455 enrolled
Sarcoma

Leiomyosarcoma, Neoplasms

NCT05153239 2026-05-13

Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)

PharmaMar

Phase 3 Completed
705 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡